Cullinan Therapeutics Inc.

This early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…

This early-stage study tests a new drug called CLN-978 in about 37 people whose rheumatoid arthritis has not responded to standard treatments. The goal is to see if the drug is safe and can control the disease by reducing certain immune cells (B cells) that drive inflammation. Pa…

This early-stage trial is testing a new drug called CLN-978 in 36 adults with active, moderate to severe Sjogren's disease. The main goal is to see if the drug is safe and tolerable, while also checking how it affects immune cells in the blood. Participants receive the drug as a …

This early-stage trial tests a new drug called CLN-049 in about 60 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals …